Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Namodenoson in advanced pancreatic adenocarcinoma
NCT06387342Phase 2Recruiting
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Nov 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of namodenoson in pancreatic adenocarcinoma (PDAC), sponsored by Can-Fite BioPharma Ltd. Primary endpoints: Adverse Events up to 1 year and Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Change from baseline up to 1 year. Started Nov 2024; status: recruiting.
02
Drugs
namodenoson
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06387342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06387342.